Rezdiffra is an innovative, once-daily medication that targets key catalysts of NASH. Remarkably, it is the first approved treatment for NASH, marking a groundbreaking advancement in the field.

Resmetirom is the first FDA-approved drug for NASH with liver fibrosis, offering a new treatment option alongside lifestyle changes. Clinical trials demonstrated significant NASH resolution and ...

In the seven weeks since Madrigal Pharmaceuticals became the first drug developer to receive Food and Drug Administration clearance for a NASH treatment, the Conshohocken company hasn't slowed down.

Rezdiffra, a once-daily oral medication targeting the liver, is the first of its kind approved by the FDA for NASH treatment. It is designed to address the core causes of NASH by acting as a ...

New York, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "NASH Treatment & Therapeutics Market Report 2023-2033" - https://www ...

And just like that, we have a crowded race to be the first approved nonalcoholic steatohepatitis (NASH) treatment—a market that could grow to $108.4 billion globally by 2030. Terns ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

The company's one clinical asset (resmetirom) has been assigned a March 14, 2024, PDUFA date, setting it up as the first-ever approved treatment for NASH. Madrigal, as predecessor VIA ...